Breakthrough Candidemia Due to Multidrug-Resistant Candida glabrata during Prophylaxis with a Low Dose of Micafungin | Zendy

Fernando César Bizerra | Zendy; Cristina JiménezOrtigosa | Zendy; Ana Carolina Remondi Souza | Zendy; Giovanni Luís Breda | Zendy; Flávio QueirozTelles | Zendy; David S. Perlin | Zendy; Arnaldo Lopes Colombo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Breakthrough Candidemia Due to Multidrug-Resistant Candida glabrata during Prophylaxis with a Low Dose of Micafungin

Author(s) -

Fernando César Bizerra,

Cristina JiménezOrtigosa,

Ana Carolina Remondi Souza,

Giovanni Luís Breda,

Flávio QueirozTelles,

David S. Perlin,

Arnaldo Lopes Colombo

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02189-13

Subject(s) - micafungin , echinocandin , candida glabrata , azole , microbiology and biotechnology , echinocandins , biology , medicine , candida albicans , pharmacology , voriconazole , caspofungin , fluconazole , antifungal

We identified a case of breakthrough candidemia in a 25-year-old patient receiving micafungin prophylaxis (50 mg/day). Five Candida glabrata isolates were obtained from blood cultures and were classified as multidrug-resistant isolates, since all of them exhibited high MICs for echinocandin and azole drugs. A mutation (S663F) in hot spot 1 of the FKS2 gene was found in all five isolates. This mutation yielded a 1,3-β-D-glucan synthase enzyme with highly reduced sensitivities to echinocandin drugs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research